Matinas BioPharma Holdings, Inc. (MTNB)
AMEX$0.55+0.02 (3.77%)
Market Cap
$2.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
721 of 924
Rank in Industry
412 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MTNB Insider Trading Activity
MTNB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular …
Insider Activity of Matinas BioPharma Holdings, Inc.
Over the last 12 months, insiders at Matinas BioPharma Holdings, Inc. have bought $0 and sold $0 worth of Matinas BioPharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Matinas BioPharma Holdings, Inc. have bought $102,650 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $16,600 was made by STERN ADAM K (director) on 2020‑08‑21.
List of Insider Buy and Sell Transactions, Matinas BioPharma Holdings, Inc.
| 2020-08-21 | STERN ADAM K | director | 20,000 0.01% | $0.83 | $16,600 | +3.36% | ||
| 2020-05-14 | LEPORE PATRICK G | director | 100,000 0.0504% | $0.73 | $73,050 | +20.81% | ||
| 2020-03-17 | Jabbour Jerome D | President and CEO | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | ||
| 2020-03-17 | STERN ADAM K | director | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | ||
| 2019-11-25 | Kucinski Keith A | Chief Financial Officer | 58,000 0.0387% | $1.23 | $71,160 | -26.55% | ||
| 2019-11-22 | Kucinski Keith A | Chief Financial Officer | 36,500 0.0234% | $1.20 | $43,807 | -27.98% | ||
| 2019-11-15 | LEPORE PATRICK G | director | 100,000 0.0623% | $1.06 | $105,530 | -19.25% | ||
| 2019-08-20 | Ende Eric J | director | 20,000 0.0126% | $0.66 | $13,200 | +23.73% | ||
| 2019-08-19 | STERN ADAM K | director | 10,400 0.0068% | $0.70 | $7,268 | +20.39% | ||
| 2019-08-19 | Jabbour Jerome D | President and CEO | 14,650 0.0093% | $0.68 | $9,975 | +20.39% | ||
| 2019-08-19 | Ende Eric J | director | 20,000 0.0127% | $0.68 | $13,650 | +20.39% | ||
| 2019-08-16 | LEPORE PATRICK G | director | 100,000 0.0655% | $0.72 | $71,850 | +17.95% | ||
| 2019-06-14 | STERN ADAM K | director | 15,000 0.0105% | $0.80 | $12,000 | +3.27% | ||
| 2019-06-12 | STERN ADAM K | director | 20,000 0.0141% | $0.80 | $15,998 | +4.19% | ||
| 2019-06-12 | Jabbour Jerome D | President and CEO | 12,487 0.0088% | $0.80 | $9,980 | +4.19% | ||
| 2019-06-10 | STERN ADAM K | director | 15,000 0.0103% | $0.82 | $12,300 | -0.91% | ||
| 2019-06-07 | STERN ADAM K | director | 20,000 0.0146% | $0.89 | $17,800 | -2.82% | ||
| 2019-05-31 | STERN ADAM K | director | 80,000 0.0547% | $0.94 | $75,200 | -13.96% | ||
| 2019-05-16 | STERN ADAM K | director | 150,000 0.1064% | $0.95 | $142,500 | -11.51% | ||
| 2019-05-16 | CONRAD HERBERT J | director | 25,000 0.018% | $0.96 | $24,115 | -11.51% |
Total: 30
Insider Historical Profitability
<0.0001%
| Rongen Roelof | Chief Executive Officer | 3539416 69.5778% | $1.88M | 1 | 0 | <0.0001% |
| STERN ADAM K | director | 3301983 64.9103% | $1.75M | 12 | 0 | <0.0001% |
| MANNINO RAPHAEL J | Chief Scientific Officer | 1424565 28.0041% | $755,019.45 | 1 | 0 | <0.0001% |
| Jabbour Jerome D | President and CEO | 799511 15.7168% | $423,740.83 | 3 | 0 | +16.76% |
| Scibetta James S | director | 418309 8.2231% | $221,703.77 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
Matinas BioPharma Holdings, Inc. (MTNB) | $1,138,733 | 28 | -4.94% | $2.7M |
$63,749,694 | 24 | -12.24% | $2.37M | |
$193,112 | 22 | -20.59% | $1.52M | |
$1,616,354 | 20 | -12.22% | $3.22M | |
$613,181 | 18 | -20.90% | $2.12M |
MTNB Institutional Investors: Active Positions
| Increased Positions | 8 | +25.81% | 52,009 | +3.93% |
| Decreased Positions | 12 | -38.71% | 1M | -78.32% |
| New Positions | 7 | New | 43,123 | New |
| Sold Out Positions | 5 | Sold Out | 934,781 | Sold Out |
| Total Postitions | 27 | -12.9% | 338,625 | -74.39% |
MTNB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $62.00 | 2.13% | 106,494 | -79,863 | -42.85% | 2024-12-31 |
| Sargent Investment Group, Llc | $37.00 | 1.28% | 64,200 | -16,040 | -19.99% | 2024-12-31 |
| Blackrock, Inc. | $29.00 | 0.99% | 49,650 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $25.00 | 0.87% | 43,467 | -3,262 | -6.98% | 2024-12-31 |
| Susquehanna International Group, Llp | $14.00 | 0.48% | 23,802 | +23,802 | New | 2024-12-31 |
| Renaissance Technologies Llc | $11.00 | 0.36% | 18,170 | +18,170 | New | 2024-12-31 |
| State Street Corp | $9.00 | 0.31% | 15,322 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $7.00 | 0.25% | 12,313 | +8,886 | +259.29% | 2024-12-31 |
| Hyman Charles D | $1.00 | 0.03% | 1,596 | 0 | 0% | 2024-06-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 1,102 | +1,102 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.